Joseph P Hagan insider trades: Regulus Therapeutics (RGLS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Joseph reports to the SEC
Open-market buys and sales
28 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 30, 2025 | RGLS | ↑ Buy | 50,000 | $1.09 | $54K | Direct | Jan 31, 2025 (1d) |
| Jan 14, 2025 | RGLS | ↓ Sell | 127,054 | $1.26 | $160K | Direct | Jan 15, 2025 (1d) |
| Jan 18, 2024 | RGLS | ↓ Sell10b5-1 | 14,580 | $1.19 | $17K | Direct | Jan 18, 2024 (0d) |
| May 19, 2023 | AUPH | ↓ Sell | 272 | $10.58 | $3K | Direct | May 23, 2023 (4d) |
| Jan 26, 2022 | RGLS | ↑ Buy | 100,000 | $0.22 | $22K | Direct | Jan 26, 2022 (0d) |
| Jan 3, 2022 | AUPH | ↓ Sell | 40,000 | $22.59 | $904K | Direct | Jan 4, 2022 (1d) |
| May 17, 2021 | RGLS | ↓ Sell | 4,186 | $0.89 | $4K | Direct | May 17, 2021 (0d) |
| Feb 16, 2021 | RGLS | ↓ Sell | 4,144 | $1.72 | $7K | Direct | Feb 17, 2021 (1d) |
| Nov 16, 2020 | RGLS | ↓ Sell | 6,094 | $0.52 | $3K | Direct | Nov 18, 2020 (2d) |
| Aug 14, 2020 | RGLS | ↓ Sell | 4,245 | $0.60 | $3K | Direct | Aug 17, 2020 (3d) |
| May 15, 2020 | RGLS | ↓ Sell | 4,426 | $0.63 | $3K | Direct | May 18, 2020 (3d) |
| Feb 18, 2020 | RGLS | ↓ Sell | 4,324 | $0.83 | $4K | Direct | Feb 19, 2020 (1d) |
| Jan 2, 2020 | RGLS | ↓ Sell | 8,345 | $0.97 | $8K | Direct | Jan 3, 2020 (1d) |
| Nov 14, 2019 | RGLS | ↓ Sell | 5,838 | $0.64 | $4K | Direct | Nov 15, 2019 (1d) |
| Oct 1, 2019 | RGLS | ↓ Sell | 8,743 | $0.68 | $6K | Direct | Oct 2, 2019 (1d) |
| Aug 15, 2019 | RGLS | ↓ Sell | 4,375 | $0.55 | $2K | Direct | Aug 16, 2019 (1d) |
| Jul 1, 2019 | RGLS | ↓ Sell | 5,783 | $1.31 | $8K | Direct | Jul 2, 2019 (1d) |
| May 16, 2019 | RGLS | ↓ Sell | 39,352 | $1.22 | $48K | Direct | May 16, 2019 (0d) |
| May 7, 2019 | RGLS | ↑ Buy | 33,194 | $1.08 | $36K | Direct | May 8, 2019 (1d) |
| Apr 1, 2019 | RGLS | ↓ Sell10b5-1 | 5,842 | $0.98 | $6K | Direct | Apr 3, 2019 (2d) |
| Jul 25, 2017 | RGLS | ↑ Buy | 219,780 | $0.91 | $200K | Direct | Jul 25, 2017 (0d) |
| Mar 3, 2016 | RGLS | ↑ Buy | 10,000 | $7.19 | $72K | Direct | Mar 7, 2016 (4d) |
| Sep 15, 2014 | OREX | ↑ Buy | 5,000 | $4.69 | $23K | Direct | Sep 15, 2014 (0d) |
| Jul 31, 2013 | OREX | ↓ Sell | 12,000 | $7.80 | $94K | Direct | Aug 2, 2013 (2d) |
| Jul 26, 2013 | OREX | ↓ Sell | 10,000 | $7.40 | $74K | Direct | Jul 29, 2013 (3d) |
| May 28, 2013 | OREX | ↓ Sell | 28,000 | $7.00 | $196K | Direct | May 30, 2013 (2d) |
| Jul 13, 2012 | OREX | ↓ Sell | 30,000 | $6.77 | $203K | Direct | Jul 13, 2012 (0d) |
| Jun 29, 2012 | OREX | ↓ Sell | 108,000 | $5.53 | $597K | Direct | Jun 29, 2012 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Joseph P Hagan's insider trades
Joseph P Hagan is Chief Executive Officer at Regulus Therapeutics (RGLS). Since Jun 29, 2012, Joseph has reported 6 open-market purchases worth $407K and 22 sales worth $2.4M on SEC Form 4. There have been no open-market trades in the last 12 months.
2 sales (1% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (43 filings), option exercises (7 filings), shares returned to the company (3 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RGLS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.